Patents/Assignees

Hangzhou Innogate Pharma Co., Ltd.

3 patents in portfolio

US12589092utility2026
Polycyclic Compound Acting as Kinase Inhibitor
0 cites
US12415797utility2025
Heterocyclic Compound as CDK-HDAC Double-channel Inhibitor
0 cites
US12358911utility2025
Heterocyclic Comipound as CDK-HDAC Dual Pathway Inhibitor
0 cites